

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM750012

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	Termination and Release of Security Interest in Certain Trademarks		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
WILMINGTON TRUST, NATIONAL ASSOCIATION, as collateral agent		08/12/2022	National Banking Association: UNITED STATES
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	COVIS PHARMA GMBH		
<b>Street Address:</b>	Grafenauweg 12		
<b>City:</b>	Zug		
<b>State/Country:</b>	SWITZERLAND		
<b>Postal Code:</b>	6301		
<b>Entity Type:</b>	Gesellschaft Mit Beschränkter Haftung (GmbH): SWITZERLAND		
<b>PROPERTY NUMBERS Total: 4</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	1504551	BETAPACE	
<b>Registration Number:</b>	2711659	BETAPACE AF	
<b>Registration Number:</b>	2383531	ZANAFLEX	
<b>Registration Number:</b>	3341341	ZANAFLEX CAPSULES	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	2124920900		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	2123733900		
<b>Email:</b>	schopra@paulweiss.com, mangelopoulos@paulweiss.com, mmcguire@paulweiss.com		
<b>Correspondent Name:</b>	Shruti Chopra		
<b>Address Line 1:</b>	1285 Avenue of the Americas		
<b>Address Line 2:</b>	Paul Weiss Rifkind Wharton & Garrison LLP		
<b>Address Line 4:</b>	New York, NEW YORK 10019-6064		
<b>ATTORNEY DOCKET NUMBER:</b>	22989-004		
<b>NAME OF SUBMITTER:</b>	Shruti Chopra		
<b>SIGNATURE:</b>	/Shruti Chopra/		
<b>DATE SIGNED:</b>	08/19/2022		

CH \$115.00 1504551

**Total Attachments: 4**

source=Covis - Certain Trademark Release (R\_F 7549\_0854) (First Lien - Wilmington Trust)#page1.tif

source=Covis - Certain Trademark Release (R\_F 7549\_0854) (First Lien - Wilmington Trust)#page2.tif

source=Covis - Certain Trademark Release (R\_F 7549\_0854) (First Lien - Wilmington Trust)#page3.tif

source=Covis - Certain Trademark Release (R\_F 7549\_0854) (First Lien - Wilmington Trust)#page4.tif

**TERMINATION AND RELEASE OF  
SECURITY INTEREST IN CERTAIN TRADEMARKS**

This Termination and Release of Security Interest in Certain Trademarks (this “Trademark Release”), effective as of August 12, 2022, is made by **WILMINGTON TRUST, NATIONAL ASSOCIATION**, as collateral agent (the “Collateral Agent”) in favor of **COVIS PHARMA GMBH**, a company incorporated under the laws of Switzerland (the “Pledgor”). Unless otherwise defined herein or the context otherwise requires, terms used in this Trademark Release, including its preamble and recitals, have the meanings provided or provided by reference in the Trademark Security Agreement (as defined below) or the Collateral Agreement (as defined below), as applicable.

W I T N E S S E T H:

WHEREAS, the Pledgor is a party to the U.S. Collateral Agreement (First Lien), dated as of January 4, 2022 (as may have been amended, supplemented or otherwise modified from time to time, the “Collateral Agreement”), in favor of the Collateral Agent;

WHEREAS, pursuant to the Collateral Agreement, the Pledgor executed and delivered that certain Notice of Grant of Security Interest in Intellectual Property (First Lien), dated as of January 4, 2022 (the “Trademark Security Agreement”) in favor of the Collateral Agent, which was recorded in the United States Patent and Trademark Office (“USPTO”) on January 4, 2022 under Reel/Frame 7549/0854;

WHEREAS, pursuant to the Trademark Security Agreement, the Pledgor, as collateral security for the payment and performance, as applicable, in full of the Secured Obligations, assigned, pledged and granted to the Collateral Agent, its successors and permitted assigns, for the benefit of the Secured Parties, a continuing security interest (the “Security Interest”) in all of its right, title and interest in, to and under the Trademark Collateral, with the Trademarks listed in Schedule A attached hereto defined as the “Released Trademark Collateral”; and

NOW, THEREFORE, in consideration of the foregoing and in exchange for good and valuable consideration, the receipt of which are hereby acknowledged, the Collateral Agent hereby (i) releases, relinquishes, terminates and discharges the Security Interest in the Released Trademark Collateral, and (ii) assigns, transfers and conveys to the Pledgor, any right, title, or interest it may have in the Released Trademark Collateral, in each case without recourse to the Collateral Agent, and without representation or warranty of any kind. This Trademark Release is applicable only and solely with respect to the Released Trademark Collateral and to no other collateral arising under the Collateral Agreement or the Trademark Security Agreement, including the remaining Trademark Collateral (collectively, the “Retained Collateral”). The Collateral Agent retains all security interests, liens and rights pledged and granted to the Collateral Agent under the Collateral Agreement and the Trademark Security Agreement with respect to the Retained Collateral, and such security interests, liens and rights shall not be, and shall not be deemed to be, released, terminated, relinquished, discharged, impaired, interrupted or otherwise modified in any

respect by this Trademark Release. Except as to the Released Trademark Collateral, the Collateral Agreement and the Trademark Security Agreement shall continue to be in full force and effect.


The Pledgor (and any successor to the Pledgor, including any person or entity hereafter having any right, title or interest in, to or under the Released Trademark Collateral) or the Pledgor's authorized representative is hereby authorized to record this Trademark Release with the USPTO.

THIS TRADEMARK RELEASE AND ANY CLAIMS, CONTROVERSY, DISPUTE OR CAUSES OF ACTION (WHETHER IN CONTRACT OR TORT OR OTHERWISE) BASED UPON, ARISING OUT OF OR RELATING TO THIS TRADEMARK RELEASE AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES UNDER THIS TRADEMARK RELEASE SHALL BE CONSTRUED IN ACCORDANCE WITH AND GOVERNED BY THE LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD TO ANY PRINCIPLE OF CONFLICTS OF LAW THAT COULD REQUIRE THE APPLICATION OF ANY OTHER LAW.

*[Signature Follows On Next Page.]*

**IN WITNESS WHEREOF**, the Collateral Agent has caused this Trademark Release to be duly executed and delivered as of the date set forth above.

**WILMINGTON TRUST, NATIONAL  
ASSOCIATION,**  
as Collateral Agent

By:  \_\_\_\_\_

Name: Andrew Lennon  
Title: Assistant Vice President

**Schedule A**  
**to**  
**Trademark Release**

*U.S. Trademark Registrations*

<b>Mark</b>	<b>Country</b>	<b>Serial Number</b>	<b>Filing Date</b>	<b>Reg. Number</b>	<b>Reg. Date</b>
Betapace	US	73701175	15 Dec 1987	1504551	20 Sep 1988
Betapace AF	US	75817196	06 Oct 1999	2711659	29 Apr 2003
Zanaflex	US	75186534	15 Oct 1996	2383531	05 Sep 2000
Zanaflex Capsules	US	78713378	15 Sep 2005	3341341	20 Nov 2007